The AMDS is an aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections ... days attributed to comorbidities and dissection-related complications.

Artivion, Inc. , a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a Late-Breaking ...

Oppenheimer reiterated its Outperform rating on Artivion Inc. (NYSE: AORT) shares, maintaining a $32.00 price target. The stock has shown remarkable momentum, delivering an 82% return over the past ...

PERSEVERE is a prospective, multicenter, nonrandomized clinical trial to determine if patients with acute DeBakey type I aortic dissection can be treated safely and effectively using the AMDS device.

This is an emergency, Conner said. About 50% of people who have an aortic dissection die at home. Of the other 50% who make ...

Eventually, they realized Earlie Smith experienced aortic dissection, a tear in the innermost layer of the aorta, which can be a life-threatening event. Doctors transferred her to the Ohio State ...

The UK’s first aortic specialist nurse has been chosen to lead a new virtual consultation service for aortic dissection patients launched by a national charity. Emma Hope, who retired from the NHS ...

Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI ... days attributed to comorbidities and dissection-related complications.